Literature DB >> 23913974

Retraction. Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance.

Vandana Chaturvedi1, Lauren W Collison, Clifford S Guy, Creg J Workman, Dario A A Vignali.   

Abstract

Entities:  

Year:  2013        PMID： 23913974      PMCID： PMC4374545          DOI： 10.4049/jimmunol.1390040

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  4 in total

1.  Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.

Authors:  Y Li; D Li; Y Li; S Wu; S Jiang; T Lin; L Xia; H Shen; J Lu
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

Review 2.  Modulation of cell signaling pathways by Phyllanthus amarus and its major constituents: potential role in the prevention and treatment of inflammation and cancer.

Authors:  Hemavathy Harikrishnan; Ibrahim Jantan; Akilandeshwari Alagan; Md Areeful Haque
Journal:  Inflammopharmacology       Date:  2019-12-02       Impact factor: 4.473

3.  Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression.

Authors:  Xiaoning Zhang; Zhiqiang Zhang; Mingyan Ju; Jiaci Li; Yaqing Jing; Yuxia Zhao; Chao Gu; Ming Dong; Guang Li; Yi Liu
Journal:  Inflammopharmacology       Date:  2020-03-13       Impact factor: 4.473

4.  IL-35 polymorphisms and cognitive decline did not show any association in patients with coronary heart disease over a 2-year period: A retrospective observational study (STROBE compliant).

Authors:  Ying Shi; Shu Zhang; Yan Xue; Zicong Yang; Yingzhong Lin; Ling Liu; Hairun Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.